Only tucatinib [18], lapatinib, and neratinib were investigated in prospective research and showed very good response premiums and reaction length. During the HER2CLIMB trial the secondary endpoint of PFS in people with brain metastases showed a substantial reduction in the risk of development or Demise by 52% within the tucatinib arm. During the